Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Molecular Therapy Oncology is Scopus-indexed (Q1, CiteScore 9.6), WoS SCIE, DOAJ. Published by Cell Press.
Checked against the index lists dated .
ISSN 2950-3299Verify ISSN ↗
Publisher: Cell Press
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 25 / 278 | 91st | Q1 |
| Oncology | 58 / 428 | 86th | Q1 |
| Molecular Medicine | 37 / 179 | 79th | Q1 |
| Cancer Research | 54 / 233 | 77th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2024–present, best quartile Q1, CiteScore 9.6.
Molecular Therapy Oncology is Q1 in Pharmacology (medical) (rank 25 of 278), Q1 in Oncology (rank 58 of 428) and Q1 in Molecular Medicine (rank 37 of 179), by CiteScore 2025. It is ranked in 4 subject areas in all.
Molecular Therapy Oncology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 9.6, which places it in quartile Q1 at the 91st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.790, quartile Q1, with an H-index of 57.
The publisher lists an article processing charge of about US$3,900 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Molecular Therapy Oncology is published by Cell Press. Its ISSN is 2950-3299.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Molecular Therapy Oncology has an h-index of 14 and a 2-year mean of 2.74 citations per paper (OpenAlex). Its Scopus CiteScore is 9.6, quartile Q1. On 2-year citations it ranks #90 of 271 Scopus journals in Pharmacology (medical).
Molecular Therapy Oncology published 167 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 89 research articles (2026), authors are most often from United States (43.6%), China (9%) and Germany (6.9%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 1 retracted paper is recorded (1.9 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.